http://link.springer.com/chapter/10.1007/978-3-319-15063-5_12
Abstract
Traumatic brain injury and stroke
remain important causes of chronic neurologic morbidity due to the lack
of vasculature in injured brain. Promising data from preclinical and
clinical studies suggest that transplantation of exogenous hematopoietic
stem cells (HSCs) and neural progenitor cells (NPCs) has therapeutic
potential for boosting brain repair. This neuroregeneration could be
achieved by HSCs/NPCs migration, differentiation, enhanced endogenous
angiogenesis and neurogenesis, and the secretion of trophic factors by
these cells in injured tissue and stroke. The neuroregeneration is
achieved by significant decrease in graft-versus-host disease and
improved functional behavior of damaged brain. Importantly, these stem
cells are derived from peripheral blood, umbilical cord blood (UCB),
bone marrow (BM), and embryonic sources. A subpopulation of CD34+
human HSCs identified by the cell-surface molecule AC133 (CD133) has
been shown to be more specific for endothelial differentiation and
vascular repair. Similarly, NPCs have shown to induced angiogenesis and
neurogenesis in stroke. Several studies have been exploited in vivo
imaging modalities, importantly magnetic resonance imaging (MRI) to
monitor the migration and engraftment efficacy of administered cells for
cell-based therapies. This chapter covers the characterization of
contrast agents, cell-labeling methods for MRI, use of endothelial
progenitor cells (EPCs) and NPCs in vascular integrity and
neuroregeneration, and molecular mechanisms of their homing to the
injured or stroke site, such as their interaction with brain endothelium
as depicted by MRI.
No comments:
Post a Comment